Wendyy Chen News Today

Findings seen among people with high-risk nonmetastatic breast cancer at a median 33.8 months.

A new study found that taking aspirin as adjuvant therapy does not improve outcomes for patients with high-risk nonmetastatic breast cancer.

Compared with placebo, daily aspirin did not improve invasive disease-free survival in patients with high-risk, HER2-negative breast cancer.

Daily aspirin use did not improve invasive disease-free survival in patients with HER2-negative breast cancer in a phase 3 trial.

Trend toward higher recurrence rate in large randomized trial